Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | APLNR | P35414 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 7/20 | 0.36 |
| ▸ | CA2 | P00918 | 6/20 | 0.36 |
| ▸ | CA12 | O43570 | 6/20 | 0.36 |
| ▸ | CA9 | Q16790 | 5/20 | 0.36 |
| ▸ | CA7 | P43166 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14744344 | 0.83 | TDP1 (0.44) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL13449471 | 0.83 | TDP1 (0.49) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL5052626 | 0.82 | TDP1 (0.49) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL4151784 | 0.81 | TDP1 (0.43) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL22950318 | 0.81 | TDP1 (0.43) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL861083 | 0.81 | TDP1 (0.46) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL12698678 | 0.80 | TDP1 (0.48) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL843323 | 0.80 | TDP1 (0.48) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL4202727 | 0.80 | TDP1 (0.48) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL31368614 | 0.80 | MEN1 (0.47) | TDP1MAOAMAOBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016029146-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | UNIVERSITY OF WASHINGTON (US) | 2016-02-25 | — | — | WO | claimed |
| US-20260109732-A1 | LIPID AMINES | MODERNATX INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20250235531-A1 | MUCOSAL ADMINISTRATION METHODS AND FORMULATIONS | MODERNATX, INC. (US) | 2025-07-24 | — | — | US | disclosed |
| EP-4475882-A1 | MUCOSAL ADMINISTRATION METHODS AND FORMULATIONS | ModernaTX, Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| WO-2024200838-A1 | NEW ODILORHABDINS ANALOGUES AS ANTIBIOTICS AGAINST MULTI-RESISTANT BACTERIA | NOSOPHARM (FR) | 2024-10-03 | — | — | WO | disclosed |
| EP-4423107-A1 | LIPID AMINES | ModernaTX, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| EP-4366829-A1 | PHENYL ACETAMIDE BASED IL-17A MODULATORS AND USES THEREOF | Dice Alpha, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| CN-117957212-A | IL-17A modulators based on phenylacetamide and uses thereof | 戴斯阿尔法公司 | 2024-04-30 | — | — | CN | disclosed |
| WO-2023076598-A1 | LIPID AMINES | MODERNATX, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023283453-A1 | PHENYL ACETAMIDE BASED IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| EP-3313832-B1 | 3-TETRAZOLYL-BENZENE-1,2-DISULFONAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME (US) | 2021-02-24 | — | — | EP | disclosed |
| US-10913736-B2 | Specific inhibitors of methionyl-tRNA synthetase | UNIVERSITY OF WASHINGTON (US) | 2021-02-09 | — | — | US | disclosed |
| US-20170275279-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | UNIVERSITY OF WASHINGTON | 2017-09-28 | — | — | US | disclosed |
| CN-106470995-A | Imidazo [1,2-a ] pyridines as soluble guanylate cyclase stimulators for the treatment of cardiovascular diseases | 拜耳医药股份有限公司 | 2017-03-01 | — | — | CN | disclosed |
| US-20170050961-A1 | IMIDAZO[1,2-A]PYRIDINES AS SOLUBLE GUANYLATE CYCLASE STIMULATORS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-02-23 | — | — | US | disclosed |
| WO-2015165933-A2 | 6-SUBSTITUTED IMIDAZO[1,2-A]PYRAZINECARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-11-05 | — | — | WO | disclosed |
| US-7888349-B2 | Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-02-15 | — | — | US | disclosed |
| US-20070167476-A1 | Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds | 3M INNOVATIVE PROPERTIES COMPANY | 2007-07-19 | — | — | US | disclosed |
| EP-1699792-A1 | PIPERAZINE, 1,4¨DIAZEPANE, 1,4¨DIAZOCANE, AND 1,5¨DIAZOCANE FUSED IMIDAZO RING COMPOUNDS | 3M Innovative Properties Company (US) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005066172-A1 | PIPERAZINE, [1,4]DIAZEPANE, [1,4]DIAZOCANE, AND [1,5]DIAZOCANE FUSED IMIDAZO RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250235531-A1 | MUCOSAL ADMINISTRATION METHODS AND FORMULATIONS | MUC1, RNMT, FABP2 | TDP1 3192/4885MAOA 3814/4885MAOB 3505/4885 |
| US-20070167476-A1 | Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds | IL4, IL2, IL5 | TDP1 2515/4885MAOA 3655/4885MAOB 4379/4885 |
| US-20170275279-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | AARS1, MTR, GARS1 | TDP1 415/4885MAOA 2382/4885MAOB 1757/4885 |
| US-20260109732-A1 | LIPID AMINES | LDLR, NPC1, PHOSPHO1 | TDP1 3880/4885MAOA 1793/4885MAOB 1873/4885 |
| US-10913736-B2 | Specific inhibitors of methionyl-tRNA synthetase | AARS1, MTR, GARS1 | TDP1 415/4885MAOA 2382/4885MAOB 1757/4885 |
| US-20170050961-A1 | IMIDAZO[1,2-A]PYRIDINES AS SOLUBLE GUANYLATE CYCLASE STIMULATORS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | GUCY1A2, GUCY1A1, GUCY1B2 | TDP1 416/4885MAOA 522/4885MAOB 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.